HRP20211965T1 - Novi selektivni inhibitori jak1 i njihova upotreba - Google Patents
Novi selektivni inhibitori jak1 i njihova upotreba Download PDFInfo
- Publication number
- HRP20211965T1 HRP20211965T1 HRP20211965TT HRP20211965T HRP20211965T1 HR P20211965 T1 HRP20211965 T1 HR P20211965T1 HR P20211965T T HRP20211965T T HR P20211965TT HR P20211965 T HRP20211965 T HR P20211965T HR P20211965 T1 HRP20211965 T1 HR P20211965T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- imidazo
- nrr
- pyridin
- pharmaceutically acceptable
- Prior art date
Links
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 101150079478 jak1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 34
- 150000003839 salts Chemical class 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 125000001475 halogen functional group Chemical group 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
- JVWXVJOIUKQBOJ-NWDGAFQWSA-N 2-[(2R,5S)-5-(4-methyl-12-oxa-3,5,8-triazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,10-pentaen-3-yl)oxan-2-yl]acetonitrile Chemical compound CC1=NC=2C(=C3C(=NC=2)C=CO3)N1[C@H]1CC[C@@H](OC1)CC#N JVWXVJOIUKQBOJ-NWDGAFQWSA-N 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- UDGHPISWLBXGGY-WDEREUQCSA-N 2-[(2R,5S)-5-[4-(hydroxymethyl)-12-oxa-3,5,8-triazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,10-pentaen-3-yl]oxan-2-yl]acetonitrile Chemical compound OCC1=NC=2C(=C3C(=NC=2)C=CO3)N1[C@H]1CC[C@@H](OC1)CC#N UDGHPISWLBXGGY-WDEREUQCSA-N 0.000 claims 3
- ZFQNHUSKKDBFHY-GRYCIOLGSA-N 2-[(2R,5S)-5-[4-[(1R)-1-hydroxyethyl]-12-oxa-3,5,8-triazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,10-pentaen-3-yl]oxan-2-yl]acetonitrile Chemical compound O[C@H](C)C1=NC=2C(=C3C(=NC=2)C=CO3)N1[C@H]1CC[C@@H](OC1)CC#N ZFQNHUSKKDBFHY-GRYCIOLGSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- -1 oxonium tetrafluoroborate Chemical compound 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 238000005984 hydrogenation reaction Methods 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 1
- ABAUJVSEICFAOS-NWDGAFQWSA-N 2-[(2R,5S)-5-(4-ethyl-12-oxa-3,5,8-triazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,10-pentaen-3-yl)oxan-2-yl]acetonitrile Chemical compound C(C)C1=NC=2C(=C3C(=NC=2)C=CO3)N1[C@H]1CC[C@@H](OC1)CC#N ABAUJVSEICFAOS-NWDGAFQWSA-N 0.000 claims 1
- UDGHPISWLBXGGY-QWRGUYRKSA-N 2-[(2S,5S)-5-[4-(hydroxymethyl)-12-oxa-3,5,8-triazatricyclo[7.3.0.02,6]dodeca-1,4,6,8,10-pentaen-3-yl]oxan-2-yl]acetonitrile Chemical compound OCC1=NC=2C(=C3C(=NC=2)C=CO3)N1[C@H]1CC[C@H](OC1)CC#N UDGHPISWLBXGGY-QWRGUYRKSA-N 0.000 claims 1
- WKNNRZVOWSSOSY-XYPYZODXSA-N C12=C(C3=C(N=C(N3[C@H]3CC[C@@H](CC3)C#N)CO)C=N2)OC=C1 Chemical compound C12=C(C3=C(N=C(N3[C@H]3CC[C@@H](CC3)C#N)CO)C=N2)OC=C1 WKNNRZVOWSSOSY-XYPYZODXSA-N 0.000 claims 1
- HIQALKYWCDEOTH-IJLUTSLNSA-N C12=C(N=CC=3N=C(N(C1=3)[C@H]1CC[C@@H](CC1)C#N)[C@@H](C)O)C=CO2 Chemical compound C12=C(N=CC=3N=C(N(C1=3)[C@H]1CC[C@@H](CC1)C#N)[C@@H](C)O)C=CO2 HIQALKYWCDEOTH-IJLUTSLNSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- WWFMBYPVXNSPOA-JHJVBQTASA-N O1C=CC2=C1C=1N(C(=NC=1C=N2)[C@H](O)C)[C@H]1CC[C@@H](CC1)CC#N Chemical compound O1C=CC2=C1C=1N(C(=NC=1C=N2)[C@H](O)C)[C@H]1CC[C@@H](CC1)CC#N WWFMBYPVXNSPOA-JHJVBQTASA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 claims 1
- LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662403660P | 2016-10-03 | 2016-10-03 | |
| PCT/US2017/054668 WO2018067422A1 (en) | 2016-10-03 | 2017-09-30 | Novel jak1 selective inhibitors and uses thereof |
| EP17858944.6A EP3509591B1 (en) | 2016-10-03 | 2017-09-30 | Novel jak1 selective inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211965T1 true HRP20211965T1 (hr) | 2022-03-18 |
Family
ID=61831161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211965TT HRP20211965T1 (hr) | 2016-10-03 | 2017-09-30 | Novi selektivni inhibitori jak1 i njihova upotreba |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | USRE50799E1 (https=) |
| EP (1) | EP3509591B1 (https=) |
| JP (1) | JP7089141B2 (https=) |
| KR (1) | KR102399848B1 (https=) |
| CN (2) | CN113214278B (https=) |
| AU (3) | AU2017339417C1 (https=) |
| DK (1) | DK3509591T3 (https=) |
| EA (1) | EA201990523A1 (https=) |
| ES (1) | ES2901216T3 (https=) |
| HK (1) | HK1253040A1 (https=) |
| HR (1) | HRP20211965T1 (https=) |
| HU (1) | HUE058120T2 (https=) |
| IL (3) | IL265358B (https=) |
| MX (1) | MX390005B (https=) |
| NZ (1) | NZ751284A (https=) |
| PL (1) | PL3509591T3 (https=) |
| PT (1) | PT3509591T (https=) |
| RS (1) | RS62695B1 (https=) |
| WO (1) | WO2018067422A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102399848B1 (ko) | 2016-10-03 | 2022-05-19 | 하이라이트ll 파머슈티컬 (하이난) 컴퍼니, 리미티드 | 신규한 jak1 선택적 억제제 및 그 용도 |
| PL3568396T3 (pl) | 2017-01-11 | 2021-05-31 | Leo Pharma A/S | Nowe pochodne aminoimidazopirydyny jako inhibitory kinaz janusowych i ich zastosowanie farmaceutyczne |
| CA3117969A1 (en) | 2018-10-31 | 2020-05-07 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
| MA55201A (fr) * | 2019-03-05 | 2022-01-12 | Incyte Corp | Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire |
| US11624751B2 (en) | 2019-03-19 | 2023-04-11 | Incyte Corporation | Biomarkers for vitiligo |
| IL318796A (en) * | 2019-06-06 | 2025-04-01 | Hangzhou Highlightll Pharmaceutical Co Ltd | Method for preparing a furoimidazopyridine compound, polymorph and salt polymorph |
| KR102785014B1 (ko) * | 2019-06-06 | 2025-03-20 | 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. | 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태 |
| CN115803317B (zh) | 2020-05-19 | 2025-07-15 | 拜耳作物科学股份公司 | 作为杀真菌化合物的氮杂双环(硫代)酰胺 |
| WO2021249995A1 (en) | 2020-06-10 | 2021-12-16 | Bayer Aktiengesellschaft | Azabicyclyl-substituted heterocycles as fungicides |
| EP4351584A4 (en) * | 2021-06-07 | 2025-04-23 | The Regents of the University of California | COMPOSITIONS AND METHODS FOR TREATING CELIAC DISEASE |
| EP4419101A4 (en) * | 2021-09-13 | 2025-09-03 | Hangzhou Highlightll Pharmaceutical Co Ltd | METHODS OF TREATMENT OF CNS DISORDERS |
| CN114213424B (zh) | 2021-12-30 | 2023-05-26 | 杭州高光制药有限公司 | 一种呋喃[3，2-b]并吡啶衍生物的合成方法 |
| WO2025224600A1 (en) * | 2024-04-21 | 2025-10-30 | Biohaven Therapeutics Ltd. | Treatment of alpha-synucleinopathies and neuroprotection |
| WO2025248468A1 (en) | 2024-05-28 | 2025-12-04 | Biohaven Therapeutics Ltd. | Use of tyk2/jak1 inhibitors to treat amyloid-related imaging abnormalities (aria) |
| WO2026002028A1 (zh) * | 2024-06-26 | 2026-01-02 | 杭州多域生物技术有限公司 | 稠杂芳环类化合物、其药物组合物及其应用 |
| WO2026032213A1 (zh) * | 2024-08-08 | 2026-02-12 | 普罗思特(南京)生物科技有限公司 | 取代的三环衍生物及其应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3983092A (en) | 1975-01-20 | 1976-09-28 | Ciba-Geigy Corporation | Phenylindane diamine mixture and epoxy resin therewith |
| US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| DE3583799D1 (de) | 1985-01-11 | 1991-09-19 | Abbott Lab Ltd | Feste zubereitung mit langsamer freisetzung. |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| DE69924735T2 (de) | 1998-07-28 | 2006-01-19 | Tanabe Seiyaku Co., Ltd. | Zur wirkstoffabgabe an zielorten im darm fähige zubereitung |
| JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US6800663B2 (en) | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
| US20070185152A1 (en) | 2004-03-02 | 2007-08-09 | Smithkline Beecham Corporation | Inhibitors of akt activity |
| CN101282974A (zh) * | 2005-08-04 | 2008-10-08 | 西特里斯药业公司 | 作为sirtuin调节剂的咪唑并吡啶衍生物 |
| CN101238186B (zh) | 2005-08-11 | 2012-10-24 | 3M创新有限公司 | 作为金属基底涂层的互穿聚合物网络及其制造方法 |
| WO2007039146A1 (en) | 2005-09-23 | 2007-04-12 | Smithkline Beecham Corporation | 4-carboxy pyrazole derivatives as anti-viral agents |
| US7879968B2 (en) | 2006-10-17 | 2011-02-01 | Taylor Made Golf Company, Inc. | Polymer compositions and golf balls with reduced yellowing |
| US20100280151A1 (en) | 2009-05-04 | 2010-11-04 | Toray Industries, Inc. | Toughened fiber reinforced polymer composite with core-shell particles |
| KR20120081164A (ko) * | 2009-09-29 | 2012-07-18 | 엑스커버리 홀딩 컴퍼니 엘엘씨 | Ｐｉ3ｋ(델타) 선택적 억제제 |
| WO2011138657A1 (en) | 2010-05-04 | 2011-11-10 | Glenmark Pharmaceuticals S.A. | Aryl substituted olefinic compounds as pde10a inhibitors |
| WO2012022045A1 (en) * | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| RU2013120966A (ru) | 2010-10-08 | 2014-11-20 | Эббви Инк. | ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| AU2012295802B2 (en) | 2011-08-12 | 2017-03-30 | Nissan Chemical Industries, Ltd. | Tricyclic heterocyclic compounds and JAK inhibitors |
| JP6057907B2 (ja) | 2011-10-04 | 2017-01-11 | 株式会社ヤクルト本社 | チアゾリジン誘導体又はその塩を有効成分とする医薬品 |
| CN104918945B (zh) | 2012-11-01 | 2018-01-05 | 因赛特公司 | 作为jak抑制剂的三环稠合噻吩衍生物 |
| CN103450125B (zh) | 2013-07-18 | 2016-01-13 | 嘉兴中科化学有限公司 | 一种5-取代苯丙呋喃-2-羧酸及其衍生物的合成方法 |
| EP3060234A1 (en) | 2013-10-24 | 2016-08-31 | AbbVie Inc. | Jak1 selective inhibitor and uses thereof |
| CN106687462A (zh) | 2014-04-30 | 2017-05-17 | 因赛特公司 | Jak1抑制剂的制备方法以及其新形式 |
| EP2940022B1 (en) | 2014-04-30 | 2020-09-02 | Masarykova Univerzita | Furopyridines as inhibitors of protein kinases |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| CN105418620B (zh) | 2014-09-23 | 2018-05-04 | 天津药明康德新药开发有限公司 | 一种4-(叔丁氧羰基)八氢呋喃并[3,2-b]吡啶-6-羧酸的合成方法 |
| WO2016100349A2 (en) | 2014-12-16 | 2016-06-23 | Rugen Holdings (Cayman) Limited | Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| CN106432232A (zh) | 2016-09-18 | 2017-02-22 | 苏州汉德创宏生化科技有限公司 | 1‑哌啶‑4‑基‑1,3‑二氢‑咪唑[4,5‑b]吡啶‑2‑酮的合成方法 |
| KR102399848B1 (ko) | 2016-10-03 | 2022-05-19 | 하이라이트ll 파머슈티컬 (하이난) 컴퍼니, 리미티드 | 신규한 jak1 선택적 억제제 및 그 용도 |
| LT3555097T (lt) | 2016-12-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai |
| CN107216334A (zh) | 2017-06-29 | 2017-09-29 | 上海吉尔多肽有限公司 | 一种6‑氯呋喃[3,2‑b]吡啶的合成方法 |
| KR102785014B1 (ko) | 2019-06-06 | 2025-03-20 | 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. | 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태 |
| IL318796A (en) | 2019-06-06 | 2025-04-01 | Hangzhou Highlightll Pharmaceutical Co Ltd | Method for preparing a furoimidazopyridine compound, polymorph and salt polymorph |
| CN118619944A (zh) | 2019-06-06 | 2024-09-10 | 北京泰德制药股份有限公司 | 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物 |
| CN114213424B (zh) | 2021-12-30 | 2023-05-26 | 杭州高光制药有限公司 | 一种呋喃[3，2-b]并吡啶衍生物的合成方法 |
-
2017
- 2017-09-30 KR KR1020197009016A patent/KR102399848B1/ko active Active
- 2017-09-30 AU AU2017339417A patent/AU2017339417C1/en active Active
- 2017-09-30 HR HRP20211965TT patent/HRP20211965T1/hr unknown
- 2017-09-30 EP EP17858944.6A patent/EP3509591B1/en active Active
- 2017-09-30 EA EA201990523A patent/EA201990523A1/ru unknown
- 2017-09-30 DK DK17858944.6T patent/DK3509591T3/da active
- 2017-09-30 PT PT178589446T patent/PT3509591T/pt unknown
- 2017-09-30 US US18/122,295 patent/USRE50799E1/en active Active
- 2017-09-30 JP JP2019517991A patent/JP7089141B2/ja active Active
- 2017-09-30 HU HUE17858944A patent/HUE058120T2/hu unknown
- 2017-09-30 CN CN202110514751.5A patent/CN113214278B/zh active Active
- 2017-09-30 RS RS20211521A patent/RS62695B1/sr unknown
- 2017-09-30 NZ NZ751284A patent/NZ751284A/en unknown
- 2017-09-30 PL PL17858944T patent/PL3509591T3/pl unknown
- 2017-09-30 CN CN201780004442.5A patent/CN108366994B/zh active Active
- 2017-09-30 HK HK18112420.5A patent/HK1253040A1/zh unknown
- 2017-09-30 ES ES17858944T patent/ES2901216T3/es active Active
- 2017-09-30 US US16/333,994 patent/US10738060B2/en not_active Ceased
- 2017-09-30 WO PCT/US2017/054668 patent/WO2018067422A1/en not_active Ceased
- 2017-09-30 US US17/526,799 patent/USRE49834E1/en active Active
- 2017-09-30 MX MX2019003649A patent/MX390005B/es unknown
-
2019
- 2019-03-13 IL IL265358A patent/IL265358B/en unknown
-
2022
- 2022-02-17 AU AU2022201061A patent/AU2022201061B2/en active Active
- 2022-02-17 AU AU2022201058A patent/AU2022201058B2/en active Active
- 2022-03-10 IL IL291265A patent/IL291265B2/en unknown
- 2022-03-10 IL IL291267A patent/IL291267B2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211965T1 (hr) | Novi selektivni inhibitori jak1 i njihova upotreba | |
| AU2022206693B2 (en) | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor | |
| JP2019537559A5 (https=) | ||
| EP3510033B1 (en) | Compounds and compositions as inhibitors of endosomal toll-like receptors | |
| JP7171444B2 (ja) | ウイルス感染治療用のジヒドロピラノピリミジン | |
| HRP20171179T1 (hr) | Amino-suostituirani imidazo[1,2-a]piridinkaboksamidi i njihova uporaba | |
| PE20130188A1 (es) | Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk | |
| RU2011121876A (ru) | Пиразолопиримидиновые соединения-ингибиторы jak и способы | |
| EA201390199A1 (ru) | 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение | |
| EA201490579A1 (ru) | Новые хиральные n-ацил-5,6,7,(8-замещенные)тетрагидро-[1,2,4]триазоло[4,3-а]пиразины как селективные антагонисты рецептора nk-3, фармацевтическая композиция, способы применения при нарушениях, опосредованных nk-3 рецепторами, и их хиральный синтез | |
| ES2899694T3 (es) | Compuestos novedosos, su síntesis y sus usos | |
| HRP20170447T1 (hr) | Spiro-prstenasti spoj koji sadrži dušik i njegova upotreba u medicini | |
| CA2953798A1 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| UA102088C2 (ru) | Производные n-азабициклических карбоксамидов, их получение и применение в терапии | |
| CA2881519A1 (en) | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors | |
| SG195085A1 (en) | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors | |
| UA102837C2 (ru) | Производные азабициклических карбоксамидов, их получение и их применение в терапии | |
| AR073551A1 (es) | Pirimidinas macrociclicas como inhibidores de proteina cinasa | |
| AR065333A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
| MX2021014320A (es) | Metodo para sintetizar el compuesto de furoimidazopiridina, sustancia polimorfica y sustancia polimorfica de sal. | |
| MX2021014319A (es) | Metodo de sintesis del compuesto de furoimidazopiridina, forma de cristal del compuesto de furoimidazopiridina, y forma de cristal de la sal del mismo. | |
| TW201524983A (zh) | 螺氧基吲哚衍生物之製造方法 | |
| AR058151A1 (es) | Compuestos antagosnistas de los receptores 2 de dopamina de rapida disociacion | |
| HRP20150697T1 (hr) | Derivati azaindola kao inhibitori proteina kinaze abi i src | |
| ES2616883T3 (es) | Derivados amida heterocíclicos como antagonistas del receptor P2X7 |